Ambrx, Inc.

Sorrento Therapeutics, Inc.

Damien Bresson

Ying Sun

Jason Pinkstaff

Richard Spence Barnett

Amha Hewet

Sandra Biroc

Timothy Buss

Tsotne Javahishvili

Shailaja Srinagesh

Nick Knudsen

Nickolas Knudsen

Jason K Pinkstaff

This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

Anti-CD70 antibody drug conjugates

The present disclosure provides anti-OX40 antibodies, and antigen-binding portions thereof. In certain embodiments, the antibodies or fragments thereof, are used for the treatment of cancer.

Anti-OX40 binding proteins

This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are &#x3b1;CD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the &#x3b1;CD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

Growing community of inventors

San Diego, CA, United States of America

Damien Bresson